Keywords
Kidney protection
Cardiac benefits
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the benefits of renal and cardiovascular protection by the use of SGLT-2 inhibitors. Bibliographic review: Dapaglifozine and other drugs of this class are responsible for inhibiting the co-carrier sodium glucose 2 and this causes a reduction in blood glucose, increased secretory function of cells β - pancreatic and increased natriuresis. In this context, a set of studies pointed to decreased risk of developing renal failure, heart failure as well as the increased survival of these patients and patients with T2DM who may or may not present complications related to these systems. Final considerations: The SGLT-2 inhibitors showed evidence of mechanisms related to renoprotection such as the induction of glycosuria, increased linear transition between reabsorption and renal glucose excretion and cardioprotectors as a decrease in pre- and post-glucoseload, improvement in diastolic function and, therefore, it is necessary to analyze its possible side effects so that the risks and benefits support its use in renal and/or cardiac patients.
References
BANERJEE S e GROBELNA A. Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetic Nephropathy: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2019.
BOCCHI EA, et al. Tópicos Emergentes em Insuficiência Cardíaca: Inibidores do Cotransportador Sódio-Glicose 2 (iSGLT2) na IC. Arquivos Brasileiros de Cardiologia, 2021; 116(2): 355-358.
DEKKERS CCJ, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab., 2018; 20(8): 1988-1993.
de JONG MA, et al. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis. Clin J Am Soc Nephrol., 2019; 14(1): 66-73.
DEKKERS CCJ, et al. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Curr Diab Rep., 2018; 18(5): 27.
FIORETTO P, et al. DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab., 2018; 20(11): 2532-2540.
GONZALEZ DE, et al. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Rev Assoc Med Bras (1992), 2020; 66Suppl 1(Suppl 1): s17-s24.
GUPTA M, et al. The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence. Ther Clin Risk Manag., 2021; 17: 823-830.
HANDELSMAN Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther., 2019; 36(10): 2567-2586.
HEERSPINK HJL, et al. DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J., 2021; 42(13): 1216-1227.
HEERSPINK HJL, et al. DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int., 2022; 101(1): 174-184.
KITADA M, et al. Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetol Int., 2020; 11(3): 245-251.
KLUGER AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol., 2019; 18(1): 99.
McMURRAY JJV, et al. DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC Heart Fail, 2021; 9(11): 807-820.
McEWAN P, et al. The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab., 2021; 23(4): 1020-1029.
NEUEN BL, et al. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant, 2020; 35(Suppl 1): i48-i55.
NINČEVIĆ V, et al. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. Int J Mol Sci., 2019; 20(23): 5831.
RHEE JJ, et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab., 2020; 22 Suppl 1(Suppl 1): 46-54.
SCHOLTES RA, et al. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial. Diabetes Care, 2021; 44(2): 440-447.
QIU M, et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res., 2021; 18(2): 14791641211011016.
WHEELER DC, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 2020; 35(10): 1700-1711.